http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
이해혁,김태희,박준식,이아룸,박용순,변동원,김민정,임희숙 대한폐경학회 2014 대한폐경학회지 Vol.20 No.3
To see the effect of dietary administration of omega 3-fatty acid formula on the vaginal cells of postmenopausal rats. Methods: Three-week-old female Wistar/ST rats were raised after one week of adjustment period. The rats were then dividedinto three groups, for three different kinds of diet; general diet, 1% omega-3 fatty acid diet, and 2% omega-3 fatty acid diet. Aftereight weeks of having assigned diet, after the oophorectomy, with the same diet previously they had Immunohistochemistry,Immunofluorescence, and Western Blot about ezrin, merlin were done. Results: In immunohistochemistry, estrogen injection group revealed thicker and well differentiated features. In Immunofluorescence,Omega-3 fatty acid composition in diet did not effect expression of ezrin and merlin in rat vagina in estrogeninjection group, their vaginal epithelium showed full layers (from basal to apical layer). In Western Blot analysis, Omega-3 fatty acidcomposition in diet did not affect expression of ezrin and merlin in rat vagina estrogen presented significant impact on expressionof ezrin and merlin. Conclusion: Although omega-3 fatty acid composition changed in diet, vaginal epithelial morphology unchanged. Estrogen dideffect on vagina cell, but omega-3 fatty acid did not effect on ezrin and merlin in vagina. (J Menopausal Med 2014;20:97-103)
이해혁 대한골다공증학회 2008 Osteoporosis and Sarcopenia Vol.6 No.1
During the perimenopause, both the quantity and quality of bone decline rapidly, resulting in a dramatic increase in the risk of fracture in postmenopausal women. Data from the large Women's Health Initiative (WHI), in which women with an intact uterus(mean age: 63 years) were randomly assigned to estrogen plus progestin, showed that HT increased total hip BMD and reduced the risk of fractures at the hip, vertebrae, and wrist. Similarly, the estrogen-alone component of the WHI, which involved women(mean age: 64 years) with prior hysterectomy, demonstrated a reduced rate of hip fracture. It is never too early in the menopause to evaluate women for bone loss and advise them on steps to take to prevent the declines in bone mass and quality that increase the risk of future osteoporosis and fracture. Postmenopausal women should therefore be screened for osteoporosis risk factors and have their BMD levels tested, if warranted, in accordance with current guidelines. Use of BMD assists physicians in diagnosing osteoporosis and in monitoring treatment effects. Low-dose hormone therapy and ultralow-dose hormone therapy can provide an effective protection against the postmenopausal decrease of BMD. Estrogen depletion after menopause become involved with postmenopausal bone loss, therefore ET(estrogen therapy) and EPT(estrogen-progestogen therapy) have been considered as first-line therapy for postmenopausal osteopenia and osteoporosis.